Full Name
Dr. Krish Patel MD
Job Title
Director, Lymphoma Research
Company/Affiliation
Sarah Cannon Research Institute
Speaker Bio
Krish Patel, MD joined Sarah Cannon Research Institute (SCRI) as Director of Lymphoma Research in 2024. He also serves as a medical oncologist at SCRI Oncology Partners in Nashville, Tenn. Previously, he served as the Director of Hematologic Malignancies and Cell Therapy at the Swedish Cancer Institute in Seattle, Washington. Dr. Patel received his undergraduate and medical degrees from Duke University School of Medicine, where he also completed post graduate training in internal medicine, hematology, and medical oncology. He further honed his research expertise through a clinical research training fellowship at the National Institutes of Health.
Clinically, Dr. Patel specializes in all aspects of clinical care of patients with lymphomas and CLL and is a specialist in the use of cellular and non-cellular immunotherapies. His research focus is the early-stage development of novel therapies including targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies. He is an active principal investigator for numerous therapeutic clinical trials (phase 1-3) in lymphomas, CLL, and cellular therapies. Dr. Patel’s research contributions have led to numerous scientific presentations at international and national scientific conferences and publications in varied medical journals including New England Journal of Medicine, Blood, and Journal of Clinical Oncology. He is also a member of the ASCO Cancer Communications Committee, the CIBMTR Lymphoma Working Committee, and the National Planning Committee for the Lymphoma Research Foundation Lymphoma Rounds.
In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL. In 2019, he was appointed as the Director of the Lymphoma Program to lead development of the program’s clinical standards for lymphoma care, assist in the programmatic expansion of cell therapy services, and to help shape the growth of the lymphoma program’s clinical research endeavors. Dr. Patel was promoted to Director of Hematology and Cellular Therapy in 2022. He served as a member of the Swedish Cancer Institute Executive Committee to oversee the continued growth of its clinical and research programs in all hematologic diseases and cellular therapy, including applications of cellular therapy in solid tumor malignancies and autoimmune diseases. Dr. Patel was also a member of the Paul G. Allen Research Center at Seattle Cancer Institute, serving as a co-founding member of the Center for Immuno-oncology, where he collaborated on translational research related to immunotherapy in hematologic diseases.
Clinically, Dr. Patel specializes in all aspects of clinical care of patients with lymphomas and CLL and is a specialist in the use of cellular and non-cellular immunotherapies. His research focus is the early-stage development of novel therapies including targeted agents, immunotherapies, and engineered cellular therapies to advance care for patients with lymphoid malignancies. He is an active principal investigator for numerous therapeutic clinical trials (phase 1-3) in lymphomas, CLL, and cellular therapies. Dr. Patel’s research contributions have led to numerous scientific presentations at international and national scientific conferences and publications in varied medical journals including New England Journal of Medicine, Blood, and Journal of Clinical Oncology. He is also a member of the ASCO Cancer Communications Committee, the CIBMTR Lymphoma Working Committee, and the National Planning Committee for the Lymphoma Research Foundation Lymphoma Rounds.
In 2016, he joined the Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy as a specialist in the care of patients with lymphomas and CLL. In 2019, he was appointed as the Director of the Lymphoma Program to lead development of the program’s clinical standards for lymphoma care, assist in the programmatic expansion of cell therapy services, and to help shape the growth of the lymphoma program’s clinical research endeavors. Dr. Patel was promoted to Director of Hematology and Cellular Therapy in 2022. He served as a member of the Swedish Cancer Institute Executive Committee to oversee the continued growth of its clinical and research programs in all hematologic diseases and cellular therapy, including applications of cellular therapy in solid tumor malignancies and autoimmune diseases. Dr. Patel was also a member of the Paul G. Allen Research Center at Seattle Cancer Institute, serving as a co-founding member of the Center for Immuno-oncology, where he collaborated on translational research related to immunotherapy in hematologic diseases.
Speaking At
